Elena Garcia-Arumí

Elena Garcia-Arumí


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
NBNuria Bujan
Nuria Bujan
CMConstanza Morén
Constanza Morén
FGFrancesc Josep García-García
Francesc Josep García-García
AEAlberto Blazquez Encinar
Alberto Blazquez Encinar
CCClara Carnicer
Clara Carnicer
GGGloria Garrabou
Gloria Garrabou
The quantification of mitochondrial respiratory chain (MRC) enzymatic activities is essential for diagnosis of a wide range of mitochondrial diseases, ranging from inherited defects to secondary dysfunctions. MRC lesion is frequently linked to extended cell damage through the generation of proton leak or oxidative stress, threatening organ viability and patient health. However, the intrinsic challenge of a methodological setup and the high variability in measuring MRC enzymatic activities represents a major obstacle for comparative analysis amongst institutions. To improve experimental and statistical robustness, seven Spanish centers with extensive experience in mitochondrial research and diagnosis joined to standardize common protocols for spectrophotometric MRC enzymatic measurements using minimum amounts of sample. Herein, we present the detailed protocols, reference ranges, tips and troubleshooting methods for experimental and analytical setups in different sample preparations and tissues that will allow an international standardization of common protocols for the diagnosis of MRC defects. Methodological standardization is a crucial step to obtain comparable reference ranges and international standards for laboratory assays to set the path for further diagnosis and research in the field of mitochondrial diseases.

5 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LCLidia Carreño-Gago
Lidia Carreño-Gago
DJDiana Luz Juárez-Flores
Diana Luz Juárez-Flores
JGJosep Grau
Josep Grau
JRJavier Ramón
Javier Ramón
ELEster Lozano
Ester Lozano
EGElena Garcia-Arumí
Elena Garcia-Arumí
Pathogenic variants in the mitochondrial tyrosyl-tRNA synthetase gene (YARS2) were associated with myopathy, lactic acidosis, and sideroblastic anemia (MLASA). However, patients can present mitochondrial myopathy, with exercise intolerance and muscle weakness, leading from mild to lethal phenotypes. Genes implicated in mtDNA replication were studied by Next Generation Sequencing (NGS) and whole exome sequence with the TruSeq Rapid Exome kit (Illumina, San Diego, CA, USA). Mitochondrial protein translation was studied following the Sasarman and Shoubridge protocol and oxygen consumption rates with Agilent Seahorse XF24 Analyzer Mitostress Test, (Agilent, Santa Clara, CA, USA). We report two siblings with two novel compound heterozygous pathogenic variants in YARS2 gene: a single nucleotide deletion in exon 1, c.314delG (p.(Gly105Alafs*4)), which creates a premature stop codon in the amino acid 109, and a single nucleotide change in exon 5 c.1391T>C (p.(Ile464Thr)), that cause a missense variant in amino acid 464. We demonstrate the pathogenicity of these new variants associated with reduced YARS2 mRNA transcript, reduced mitochondrial protein translation and dysfunctional organelle function. These pathogenic variants are responsible for late onset MLASA, herein accompanied by pancreatic insufficiency, observed in both brothers, clinically considered as Pearson’s syndrome. Molecular study of YARS2 gene should be considered in patients presenting Pearson’s syndrome characteristics and MLASA related phenotypes.

23 March 2023 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
JRJuan Luis Restrepo-Vera
Juan Luis Restrepo-Vera
EREulàlia Rovira-Moreno
Eulàlia Rovira-Moreno
JRJavier Ramón
Javier Ramón
MCMarta Codina-Sola
Marta Codina-Sola
ALArnau Llauradó
Arnau Llauradó
RJRaul Juntas-Morales
Raul Juntas-Morales